IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Is the Application of

Florence Bordon-Pallier, et al

Examiner:

To Be Assigned

Art Unit:

To Be Assigned

Application No.:

10/606/424

Filed:

M

June 26, 2003

Title: Novel Purine Derivatives, Preparation Method and Use as Medicines

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

November 13, 2003
Date of Deposit

Bonnie Steir Signature

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

J	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.							
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113							
		or a notice of allowance under §1.311, whichever occurs first.								
		(1)	The undersigned attorney certifies that each item of information contained in this							
			Information Disclosure Statement was cited in a communication from a foreign							
			patent office in a counterpart foreign application not more than three months prior							
			to the filing of this statement;							
		(2)	The undersigned attorney certifies that no item of information contained in this							
			Information Disclosure Statement was cited in a communication from a foreign							
			patent office in a counterpart foreign application or, to the knowledge of the							
			undersigned attorney after making reasonable inquiry, was known to any							
			individual designated in §1.56(c) more than three months prior to the filing of this							
			statement; or							
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in							
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is							
			authorized.							

For your information, US Patent 6,413,754 B1 is the English equivalent of WO 99/07836. Also enclosed, for the Examiner's convenience, is a copy of the International Search Report.

Respectfully submitted,

Irving Newman, Reg. No. 22,638 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2785 (908) 231-2626 Telefax Aventis Docket No. 2541US CNT ign Linside this bo

Please type a plus sign inside this box.

Approved for use through 10/3/199. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/P	то		Compl te if Known			
				Application Number	10/606,424		
INFO	RMATIO	N DISC	LOSURE	Filing Date (06-26-2003		
STAT	TEMENT	BY API	PLICANT	First Named Inventor	BORDON-PALLIER		
				Group Art Unit			
(use as many sh	eets as nec	essary)	Examiner Name	· _		
heet	1	of	2	Attorney Docket Number	2541 - US - CNT		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent I Number	Document Kind Code ² (if known)	of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		6,413,754 B1		FAY et al.	07-02-2002			
			_					
		-						
			_					
		 						
		1						
		 						
	-							
					- ' -			
		I	I					

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		wo	00/49018		IMBACH, et al	08-24-2000		\top
		wo	97/16452		ZIMMERMANN, et al	05-09-1997		T
		wo	97/20842		MEIJER, et al	06-12-1997		\top
		WO	98/05335		LUM, et al	02-12-1998		1
		wo	99/07705		GRAY, et al	02-18-1999		T
		wo	99/07836		FAYE et al.	02-18-1999		$oldsymbol{\perp}$
						 		+
								上
				1 1				

Examiner	Date	
Signature	Considered	l i

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/PT	·o		Complete if Kn wn		
				Application Number	10/606,424	
INFO	PRMATIO	N D	ISCLOSURE	Filing Date	06-26-2003	
STA	TEMENT	BY	APPLICANT	First Named Inventor	BORDON-PALLIER	
0				Group Art Unit		
	(use as many	sheets	as necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2541 - US - CNT	

	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		KOZIMA S et al., Formation of Organotin-Nitrogen Bonds III*. N-Trialkyltin-5-Subsituted Tetrazoles, J. Organometallic Chemistry, Vol. 33, 1971, pp 337-346	
-			\sqcup

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.